Alvea is a startup biotechnology company focused on building a streamlined platform for developing and deploying DNA vaccines against COVID-19 variants and other pathogens. It launched in February 2022.^[1]

Further reading

Fish, Kyle (2022) Announcing Alvea—An EA COVID vaccine project, Effective Altruism Forum, February 16.

External links

Alvea. Official website.

Apply for a job.

Related entries

biosecurity | COVID-19 pandemic | pandemic preparedness | vaccines

1. ^

   PR Newswire (2022) Alvea launches scalable, shelf- stable DNA vaccine development against new SARS-CoV-2 variants, PR Newswire, February 16.